| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| MNKDMannKind Corporation | 1.71B | 5.58 | 57.41 | 43.5% | 9.32% | 1.92% | ||
| CORTCorcept Therapeutics Incorporated | 3.72B | 35.39 | 28.77 | 39.94% | 14.19% | 16.65% | 5.26% | 0.01 |
| GUTSFractyl Health, Inc. Common Stock | 302.14M | 1.97 | -1.22 | -22.5% | -40732.33% | -241.68% | 2.20 | |
| LXRXLexicon Pharmaceuticals, Inc. | 465.15M | 1.28 | -2.03 | 24.81% | -96.77% | -57.07% | 0.74 | |
| RZLTRezolute, Inc. | 260.56M | 2.81 | -2.87 | -52.45% | 0.01 | |||
| MISTMilestone Pharmaceuticals Inc. | 172.89M | 2.03 | -3.03 | -100% | -282.97% | 4.17 | ||
| ALTAltimmune, Inc. | 442.41M | 4.24 | -3.16 | -95.31% | -4195.75% | -45.21% | 0.01 | |
| BIOABioAge Labs, Inc. | 771.24M | 21.51 | -3.24 | -12.81% | -27.32% | 0.03 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 3.15M | 23.64M | 77.43M | 130.13M |
| Revenue Growth % | - | - | - | - | - | - | - | 6.49% | 2.28% | 0.68% |
| Cost of Goods Sold | 0 | 144K | 223K | 442K | 834K | 690K | 599K | 2.13M | 9.3M | 13.37M |
| COGS % of Revenue | - | - | - | - | - | - | 0.19% | 0.09% | 0.12% | 0.1% |
| Gross Profit | 0 | -144K | -223K | -442K | -834K | -690K | 2.56M | 21.5M | 68.13M | 116.76M |
| Gross Margin % | - | - | - | - | - | - | 0.81% | 0.91% | 0.88% | 0.9% |
| Gross Profit Growth % | - | - | -0.55% | -0.98% | -0.89% | 0.17% | 4.7% | 7.42% | 2.17% | 0.71% |
| Operating Expenses | 10.57M | 25.91M | 32.41M | 78.42M | 145.17M | 135.88M | 172.61M | 200.66M | 252.48M | 382.26M |
| OpEx % of Revenue | - | - | - | - | - | - | 54.73% | 8.49% | 3.26% | 2.94% |
| Selling, General & Admin | 3.42M | 6.31M | 9.52M | 28.08M | 36.55M | 46.13M | 68.49M | 92.03M | 117.53M | 144.3M |
| SG&A % of Revenue | - | - | - | - | - | - | 21.71% | 3.89% | 1.52% | 1.11% |
| Research & Development | 7.15M | 19.59M | 22.89M | 50.34M | 109.45M | 90.45M | 104.13M | 108.63M | 134.95M | 237.96M |
| R&D % of Revenue | - | - | - | - | - | - | 33.01% | 4.6% | 1.74% | 1.83% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | -834K | -690K | 0 | 0 | 0 | 0 |
| Operating Income | -10.57M | -25.91M | -32.41M | -78.42M | -146M | -136.57M | -170.06M | -179.16M | -184.36M | -265.5M |
| Operating Margin % | - | - | - | - | - | - | -53.92% | -7.58% | -2.38% | -2.04% |
| Operating Income Growth % | -0.63% | -1.45% | -0.25% | -1.42% | -0.86% | 0.06% | -0.25% | -0.05% | -0.03% | -0.44% |
| EBITDA | -10.07M | -25.76M | -32.19M | -77.97M | -145.17M | -135.88M | -168.9M | -177.49M | -182.6M | -263.94M |
| EBITDA Margin % | - | - | - | - | - | - | -53.55% | -7.51% | -2.36% | -2.03% |
| EBITDA Growth % | - | -1.56% | -0.25% | -1.42% | -0.86% | 0.06% | -0.24% | -0.05% | -0.03% | -0.45% |
| D&A (Non-Cash Add-back) | 500K | 144K | 223K | 442K | 834K | 690K | 1.16M | 1.67M | 1.76M | 1.56M |
| EBIT | -11.07M | -25.91M | -32.41M | -78.42M | -146M | -136.57M | -69.61M | -175.92M | -170.22M | -239.65M |
| Net Interest Income | 0 | 0 | 0 | 0 | 5.27M | 2.58M | 447K | -1.17M | 53K | -5.89M |
| Interest Income | 0 | 33K | 566K | 4.35M | 5.27M | 2.58M | 447K | 4.03M | 13.95M | 14.71M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.2M | 13.89M | 20.6M |
| Other Income/Expense | -500K | 33K | -1.3M | 4.35M | 5.27M | 2.58M | 100.45M | -1.96M | 243K | 5.25M |
| Pretax Income | -11.07M | -25.87M | -33.71M | -74.06M | -140.73M | -134M | -69.61M | -181.12M | -184.11M | -260.26M |
| Pretax Margin % | - | - | - | - | - | - | -22.07% | -7.66% | -2.38% | -2% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 564K | 346K |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 0.96% | 0.98% | 1% | 1% | 1% | 1% |
| Net Income | -11.07M | -25.87M | -33.71M | -74.06M | -134.62M | -130.73M | -69.61M | -181.12M | -184.68M | -260.6M |
| Net Margin % | - | - | - | - | - | - | -22.07% | -7.66% | -2.39% | -2% |
| Net Income Growth % | -0.71% | -1.34% | -0.3% | -1.2% | -0.82% | 0.03% | 0.47% | -1.6% | -0.02% | -0.41% |
| Net Income (Continuing) | -11.07M | -25.87M | -33.71M | -74.06M | -140.73M | -134M | -69.61M | -181.12M | -184.68M | -260.6M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.09 | -1.55 | -1.26 | -2.39 | -3.70 | -2.96 | -1.37 | -3.51 | -3.20 | -4.34 |
| EPS Growth % | -0.7% | -0.42% | 0.19% | -0.9% | -0.55% | 0.2% | 0.54% | -1.56% | 0.09% | -0.36% |
| EPS (Basic) | -1.09 | -1.55 | -1.26 | -2.39 | -3.70 | -2.96 | -1.37 | -3.51 | -3.20 | -4.34 |
| Diluted Shares Outstanding | 10.2M | 16.73M | 26.73M | 31M | 36.42M | 44.13M | 49.6M | 52.12M | 57.67M | 60.99M |
| Basic Shares Outstanding | 10.2M | 16.73M | 26.73M | 31M | 36.42M | 44.13M | 49.6M | 52.12M | 57.67M | 60.99M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 35.49M | 11.18M | 150.67M | 258.69M | 302.4M | 181.67M | 308.39M | 354.24M | 308.27M | 374.2M |
| Cash & Short-Term Investments | 34.87M | 10.54M | 148.08M | 252.06M | 292.46M | 172.79M | 294.86M | 333.29M | 275.85M | 320.56M |
| Cash Only | 34.87M | 6.54M | 34.24M | 49.54M | 62.29M | 100.85M | 59.25M | 127.68M | 60.08M | 89.14M |
| Short-Term Investments | 0 | 4M | 113.85M | 202.52M | 230.16M | 71.94M | 235.61M | 205.61M | 215.76M | 231.43M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 1.02M | 6.22M | 14.87M | 18.51M |
| Days Sales Outstanding | - | - | - | - | - | - | 118.62 | 96.11 | 70.08 | 51.93 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 111K | 2.92M | 8.62M | 18.74M |
| Days Inventory Outstanding | - | - | - | - | - | - | 67.64 | 499.16 | 338.4 | 511.7 |
| Other Current Assets | 623K | 216K | 1.06M | 1.34M | 3.51M | 3.05M | 3.99M | 7.42M | 6.67M | 8.8M |
| Total Non-Current Assets | 1.78M | 1.16M | 1.06M | 1.52M | 6.12M | 5.41M | 21.14M | 28.25M | 24.48M | 18.07M |
| Property, Plant & Equipment | 17K | 930K | 840K | 1.12M | 5.72M | 5M | 4.33M | 3.38M | 2.12M | 4.11M |
| Fixed Asset Turnover | - | - | - | - | - | - | 0.73x | 7.00x | 36.49x | 31.67x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 4.66M | 7.88M | 7.03M | 6.17M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 1.77M | 234K | 225K | 401K | 403K | 403K | 12.14M | 16.98M | 15.33M | 7.79M |
| Total Assets | 37.27M | 12.34M | 151.74M | 260.21M | 308.52M | 187.07M | 329.52M | 382.48M | 332.75M | 392.27M |
| Asset Turnover | - | - | - | - | - | - | 0.01x | 0.06x | 0.23x | 0.33x |
| Asset Growth % | 191.14% | -0.67% | 11.3% | 0.71% | 0.19% | -0.39% | 0.76% | 0.16% | -0.13% | 0.18% |
| Total Current Liabilities | 5.27M | 4.73M | 6.72M | 13.58M | 24.42M | 17.99M | 43.43M | 39.81M | 55.2M | 115.52M |
| Accounts Payable | 1.43M | 1.9M | 2.43M | 7.64M | 10.41M | 4.9M | 5.74M | 4.8M | 4.88M | 12.33M |
| Days Payables Outstanding | - | 4.8K | 3.97K | 6.31K | 4.56K | 2.59K | 3.5K | 820.87 | 191.68 | 336.6 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 1000K | 1000K | 1000K | 1000K |
| Other Current Liabilities | 249K | 156K | 101K | 60K | 377K | 180K | 800K | 2.42M | 5.41M | 43.59M |
| Current Ratio | 6.73x | 2.36x | 22.42x | 19.05x | 12.38x | 10.10x | 7.10x | 8.90x | 5.58x | 3.24x |
| Quick Ratio | 6.73x | 2.36x | 22.42x | 19.05x | 12.38x | 10.10x | 7.10x | 8.83x | 5.43x | 3.08x |
| Cash Conversion Cycle | - | - | - | - | - | - | -3.31K | -225.6 | 216.8 | 227.03 |
| Total Non-Current Liabilities | 0 | 311K | 228K | 372K | 3.09M | 2.55M | 1.95M | 78.41M | 107.78M | 112.21M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 3.09M | 2.55M | 1.95M | 1.26M | 490K | 3.94M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 311K | 228K | 372K | 0 | 0 | 0 | 77.15M | 107.29M | 108.27M |
| Total Liabilities | 5.27M | 5.04M | 6.95M | 13.95M | 27.5M | 20.55M | 45.37M | 118.22M | 162.99M | 227.72M |
| Total Debt | 0 | 0 | 0 | 0 | 3.56M | 3.09M | 2.55M | 1.94M | 1.26M | 3.94M |
| Net Debt | -34.87M | -6.54M | -34.24M | -49.54M | -58.74M | -97.77M | -56.7M | -125.73M | -58.82M | -85.2M |
| Debt / Equity | - | - | - | - | 0.01x | 0.02x | 0.01x | 0.01x | 0.01x | 0.02x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - | -34.45x | -13.27x | -12.89x |
| Total Equity | 32M | 7.3M | 144.79M | 246.26M | 281.02M | 166.53M | 284.15M | 264.26M | 169.76M | 164.55M |
| Equity Growth % | 90.39% | -0.77% | 18.84% | 0.7% | 0.14% | -0.41% | 0.71% | -0.07% | -0.36% | -0.03% |
| Book Value per Share | 3.14 | 0.44 | 5.42 | 7.94 | 7.72 | 3.77 | 5.73 | 5.07 | 2.94 | 2.70 |
| Total Shareholders' Equity | 32M | 7.3M | 144.79M | 246.26M | 281.02M | 166.53M | 284.15M | 264.26M | 169.76M | 164.55M |
| Common Stock | 93K | 10K | 27K | 34K | 44K | 44K | 50K | 56K | 59K | 61K |
| Retained Earnings | -50.67M | -76.54M | -110.25M | -184.6M | -325.33M | -459.33M | -528.94M | -710.06M | -894.74M | -1.16B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | -144K | 0 | 0 | 0 | 49K | -1K | -92K | 134K | -39K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -6.98M | -23.22M | -29.46M | -62.06M | -122.75M | -121.98M | -146M | -173.43M | -136.16M | -113.88M |
| Operating CF Margin % | - | - | - | - | - | - | -46.29% | -7.34% | -1.76% | -0.88% |
| Operating CF Growth % | 0.07% | -2.33% | -0.27% | -1.11% | -0.98% | 0.01% | -0.2% | -0.19% | 0.21% | 0.16% |
| Net Income | -11.07M | -25.87M | -33.71M | -74.06M | -140.73M | -134M | -69.61M | -181.12M | -184.68M | -260.6M |
| Depreciation & Amortization | 0 | 144K | 223K | 442K | 834K | 690K | 1.16M | 1.67M | 1.76M | 1.56M |
| Stock-Based Compensation | 298K | 1.17M | 2.28M | 6.39M | 11.88M | 17.45M | 20.8M | 19.83M | 32.55M | 39.68M |
| Deferred Taxes | 0 | 0 | 1.86M | 0 | 0 | 0 | -100M | 0 | 0 | 0 |
| Other Non-Cash Items | 1.42M | 11K | -76K | 4.51M | 203K | -234K | -250K | 5.91M | 9.4M | 94.9M |
| Working Capital Changes | 2.38M | 1.33M | -39K | 667K | 5.07M | -5.89M | 1.9M | -19.72M | 4.81M | 10.57M |
| Change in Receivables | -60K | 0 | 0 | 0 | 0 | 0 | -1.25M | -5.2M | -8.64M | -3.65M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | -11K | -2.81M | -5.71M | -10.12M |
| Change in Payables | 3.84M | 467K | 1.95M | 6.95M | 10.51M | -6.45M | 18.31M | 1.54M | 14.77M | 21.92M |
| Cash from Investing | -17K | -5.11M | -110.04M | -87.15M | -27.97M | 158.53M | -62.16M | 28.03M | -5.67M | -48.17M |
| Capital Expenditures | -17K | -1.06M | -133K | -722K | -3.38M | -214K | -5.43M | -4.28M | -47K | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | 1.72% | 0.18% | 0% | - |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -4.05M | -109.91M | -86.43M | -24.59M | 0 | 7M | -4M | -5.67M | -40.5M |
| Cash from Financing | 41.71M | 0 | 167.2M | 164.69M | 163.47M | 2.01M | 166.48M | 213.83M | 74.37M | 191.24M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -3.97M |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 2.09M | 0 | 700K | 1.81M | 2.12M | 2.01M | 4.75M | 82.72M | 25.49M | 12.87M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -6.99M | -24.28M | -29.59M | -62.78M | -126.14M | -122.19M | -151.44M | -177.71M | -136.2M | -113.88M |
| FCF Margin % | - | - | - | - | - | - | -48.01% | -7.52% | -1.76% | -0.88% |
| FCF Growth % | 0.07% | -2.47% | -0.22% | -1.12% | -1.01% | 0.03% | -0.24% | -0.17% | 0.23% | 0.16% |
| FCF per Share | -0.69 | -1.45 | -1.11 | -2.02 | -3.46 | -2.77 | -3.05 | -3.41 | -2.36 | -1.87 |
| FCF Conversion (FCF/Net Income) | 0.63x | 0.90x | 0.87x | 0.84x | 0.91x | 0.93x | 2.10x | 0.96x | 0.74x | 0.44x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -69.99% | -131.67% | -44.33% | -37.88% | -51.06% | -58.42% | -30.89% | -66.05% | -85.1% | -155.91% |
| Return on Invested Capital (ROIC) | - | - | -43.68% | -38.28% | -52.27% | -70.39% | -86.12% | -73.43% | -110.85% | -209.29% |
| Gross Margin | - | - | - | - | - | - | 81.01% | 90.98% | 87.99% | 89.73% |
| Net Margin | - | - | - | - | - | - | -2207.1% | -766.22% | -238.52% | -200.27% |
| Debt / Equity | - | - | - | - | 0.01x | 0.02x | 0.01x | 0.01x | 0.01x | 0.02x |
| Interest Coverage | - | - | - | - | - | - | - | -34.45x | -13.27x | -12.89x |
| FCF Conversion | 0.63x | 0.90x | 0.87x | 0.84x | 0.91x | 0.93x | 2.10x | 0.96x | 0.74x | 0.44x |
| Revenue Growth | - | - | - | - | - | - | - | 649.46% | 227.56% | 68.06% |
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Product | - | 77.43M | 130.13M |
| Product Growth | - | - | 68.06% |
| Product revenue | 16.88M | - | - |
| Product revenue Growth | - | - | - |
| License revenue | 6.75M | - | - |
| License revenue Growth | - | - | - |
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| UNITED STATES | - | 62.42M | 96.11M |
| UNITED STATES Growth | - | - | 53.96% |
| Non-US | - | - | 34.02M |
| Non-US Growth | - | - | - |
| Other Countries | - | 8.93M | - |
| Other Countries Growth | - | - | - |
| GERMANY | - | 6.08M | - |
| GERMANY Growth | - | - | - |
Rhythm Pharmaceuticals, Inc. (RYTM) reported $174.3M in revenue for fiscal year 2024.
Rhythm Pharmaceuticals, Inc. (RYTM) grew revenue by 68.1% over the past year. This is strong growth.
Rhythm Pharmaceuticals, Inc. (RYTM) reported a net loss of $192.3M for fiscal year 2024.
Rhythm Pharmaceuticals, Inc. (RYTM) does not currently pay a meaningful dividend. The company may be reinvesting profits for growth.
Rhythm Pharmaceuticals, Inc. (RYTM) has a return on equity (ROE) of -155.9%. Negative ROE indicates the company is unprofitable.
Rhythm Pharmaceuticals, Inc. (RYTM) had negative free cash flow of $109.1M in fiscal year 2024, likely due to heavy capital investments.